Synthetic Conjugated Estrogens, B

Identification

Name
Synthetic Conjugated Estrogens, B
Accession Number
DB09318
Type
Small Molecule
Groups
Approved
Description

Synthetic conjugated estrogens, B tablets contain a blend of ten synthetic estrogenic substances. The estrogenic substances are: sodium estrone sulfate, sodium equilin sulfate, sodium 17α-dihydroequilin sulfate, sodium 17α-estradiol sulfate, sodium 17β­ dihydroequilin sulfate, sodium 17α-dihydroequilenin sulfate, sodium 17β-dihydroequilenin sulfate, sodium equilenin sulfate, sodium 17β-estradiol sulfate, and sodium Δ8,9-dehydroestrone sulfate. This blend of ten estrogen derivatives are plant-derived forms of endogenous estrogens and contain many of the same compounds as the Conjugated Equine Estrogens (CEEs), although they are not considered to be equivalent. Available as the product Cenestin (FDA), this combination of plant-derived estrogenic compounds is indicated for the treatment of moderate to severe vasomotor symptoms, vulvovaginal atrophy, vaginal dryness, and paint with intercourse associated with menopause.

All estrogen products mimic the effects of endogenous estrogens in the body which are responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Estrogens act by binding to estrogen receptors on a wide variety of tissues in the body and modulating the pituitary secretion of the gonadotropins, luteinizing hormone (LH) and follicle stimulating hormone (FSH) through a negative feedback mechanism. Prior to menopause, the primary source of estrogen is the ovarian follicle, which secretes 70-500 micrograms of estradiol daily, depending on the phase of the menstrual cycle. However, once a woman stops ovulating there is a sharp decline in the production of progesterone and estradiol by the ovaries and a consequent fluctuation in LH and FSH due to a lack of feedback control. This shift in hormone production is largely responsible for many of the symptoms experienced during and after menopause and includes hot flashes and other vasomotor symptoms, painful intercourse, vaginal dryness, and vulvovaginal atrophy. These symptoms are able to be reduced by replacing many of the hormones lost during and following menopause with synthetic or naturally occurring forms, in a therapy known as Hormone Replacement Therapy (HRT).

Pharmacologic estrogen products are available in a variety of formats. Although many of them contain several compounds in common (such as the estrogen derivatives sodium estrone sulfate and sodium equilin sulfate), they vary by their original source (such as horse-, human-, or plant-derived), and the remaining mixture of estrogenic derivatives. Conjugated Equine Estrogens (CEEs) are derived from the urine of pregnant mares and contain a blend of at least 10 estrogen derivatives. Marketed under the brand name Premarin, CEEs are the most frequently used form of conjugated estrogens. There is currently no generic form of CEEs available as a detailed analytical characterization of the active ingredients or of their estrogenic activity is not available at this time. Conjugated estrogens are also available in a plant-derived synthetic form that replicates the naturally occurring, horse-derived forms. Available as either "Synthetic Conjugated Estrogens, A" containing 9 estrogen derivatives (available as Cenestin) or as "Synthetic Conjugated Estrogens, B" containing 10 estrogen derivatives (available as Enjuvia), these products are isolated as precursors from yam or soy plants and then chemically modified to mimic the products available in their naturally occurring form.

Synonyms
  • Estrogens, Conjugated Synthetic B
External IDs
CE 10 / CE-10 / CE10
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
EnjuviaTablet, film coated.3 mg/1OralTeva Women's Health2006-04-242017-04-30Us51285 0406 02 nlmimage10 e91ff4af
EnjuviaTablet.3 mg/1OralPhysicians Total Care, Inc.2010-09-03Not applicableUs
EnjuviaTablet, film coated.9 mg/1OralTeva Women's Health2007-09-282017-01-31Us51285 0409 02 nlmimage10 093584ac
EnjuviaTablet.625 mg/1OralPhysicians Total Care, Inc.2010-09-03Not applicableUs
EnjuviaTablet, film coated.45 mg/1OralTeva Women's Health2006-04-242017-04-30Us51285 0407 02 nlmimage10 0e35871c
EnjuviaTablet.9 mg/1OralPhysicians Total Care, Inc.2010-09-03Not applicableUs
EnjuviaTablet, film coated1.25 mg/1OralTeva Women's Health2006-04-242016-09-30Us51285 0410 02 nlmimage10 0435826c
Categories
UNII
8L6LAK9BTR
CAS number
Not Available
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

For the treatment of moderate to severe vasomotor symptoms due to menopause and for the treatment of moderate to severe vaginal dryness, pain with intercourse, and symptoms of vulvar and vaginal atrophy due to menopause.

Structured Indications
Pharmacodynamics
Not Available
Mechanism of action

All estrogen products mimic the effects of endogenous estrogens in the body which are responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Estrogens act by binding to estrogen receptors on a wide variety of tissues in the body and modulating the pituitary secretion of the gonadotropins, luteinizing hormone (LH) and follicle stimulating hormone (FSH) through a negative feedback mechanism. Prior to menopause, the primary source of estrogen is the ovarian follicle, which secretes 70-500 micrograms of estradiol daily, depending on the phase of the menstrual cycle. However, once a woman stops ovulating there is a sharp decline in the production of progesterone and estradiol by the ovaries and a consequent fluctuation in LH and FSH due to a lack of feedback control. This shift in hormone production is largely responsible for many of the symptoms experienced during and after menopause and includes hot flashes and other vasomotor symptoms, painful intercourse, vaginal dryness, and vulvovaginal atrophy. These symptoms are able to be reduced by replacing many of the hormones lost during and following menopause with synthetic or naturally occurring forms, in a therapy known as Hormone Replacement Therapy (HRT).

TargetActionsOrganism
AEstrogen receptor alpha
ligand
Human
Absorption

Synthetic conjugated estrogens, B are soluble in water and are well absorbed from the gastrointestinal tract after release from the drug formulation. The tablets release synthetic conjugated estrogens, B slowly over a period of several hours.

Volume of distribution

The distribution of exogenous estrogens is similar to that of endogenous estrogens. Estrogens are widely distributed in the body and are generally found in higher concentrations in the sex hormone target organs.

Protein binding

Estrogens circulate in the blood largely bound to sex hormone binding globulin (SHBG) and albumin.

Metabolism

Exogenous estrogens are metabolized in the same manner as endogenous estrogens. Circulating estrogens exist in a dynamic equilibrium of metabolic interconversions. These transformations take place mainly in the liver. Estradiol is converted reversibly to estrone, and both can be converted to estriol, which is the major urinary metabolite. Estrogens also undergo enterohepatic recirculation via sulfate and glucuronide conjugation in the liver, biliary secretion of conjugates into the intestine, and hydrolysis in the intestine followed by reabsorption. In postmenopausal women, a significant portion of the circulating estrogens exists as sulfate conjugates, especially estrone sulfate, which serves as a circulating reservoir for the formation of more active estrogens. In vitro and in vivo studies have shown that estrogens are metabolized partially by cytochrome P450 3A4 (CYP3A4).

Route of elimination

Estradiol, estrone, and estriol are excreted in the urine along with glucuronide and sulfate conjugates.

Half life

The half life of baseline-corrected estrone and equilin was found to be 23.46 hr and 15.09 hr, respectively.

Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Investigational
19-norandrostenedioneThe serum concentration of 19-norandrostenedione can be increased when it is combined with Synthetic Conjugated Estrogens, B.Experimental, Illicit
5-androstenedioneThe serum concentration of 5-androstenedione can be increased when it is combined with Synthetic Conjugated Estrogens, B.Experimental, Illicit
AbciximabSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Abciximab.Approved
AcenocoumarolSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Acenocoumarol.Approved
AlclometasoneThe serum concentration of Alclometasone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Experimental, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be increased when it is combined with Synthetic Conjugated Estrogens, B.Experimental, Investigational
AmcinonideThe serum concentration of Amcinonide can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
AminophyllineThe serum concentration of Aminophylline can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
AmiodaroneThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Amiodarone.Approved, Investigational
AnastrozoleThe therapeutic efficacy of Anastrozole can be decreased when used in combination with Synthetic Conjugated Estrogens, B.Approved, Investigational
AncrodSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Ancrod.Investigational
AndrostenedioneThe serum concentration of Androstenedione can be increased when it is combined with Synthetic Conjugated Estrogens, B.Experimental, Illicit
AnecortaveThe serum concentration of Anecortave can be increased when it is combined with Synthetic Conjugated Estrogens, B.Investigational
anecortave acetateThe serum concentration of anecortave acetate can be increased when it is combined with Synthetic Conjugated Estrogens, B.Investigational
Anthrax immune globulin humanSynthetic Conjugated Estrogens, B may increase the thrombogenic activities of Anthrax immune globulin human.Approved
Antithrombin III humanSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Antithrombin III human.Approved
ApixabanSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Apixaban.Approved
AprepitantThe serum concentration of Synthetic Conjugated Estrogens, B can be increased when it is combined with Aprepitant.Approved, Investigational
ArdeparinSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Argatroban.Approved, Investigational
AtamestaneThe serum concentration of Atamestane can be increased when it is combined with Synthetic Conjugated Estrogens, B.Investigational
AtazanavirThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Atomoxetine.Approved
BecaplerminSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved, Investigational
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved, Vet Approved
BivalirudinSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Bivalirudin.Approved, Investigational
BoceprevirThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Synthetic Conjugated Estrogens, B can be decreased when it is combined with Bosentan.Approved, Investigational
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
Capromab pendetideSynthetic Conjugated Estrogens, B may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
CarbamazepineThe metabolism of Synthetic Conjugated Estrogens, B can be increased when combined with Carbamazepine.Approved, Investigational
CelecoxibCelecoxib may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B.Approved, Investigational
CeritinibThe serum concentration of Synthetic Conjugated Estrogens, B can be increased when it is combined with Ceritinib.Approved
CertoparinSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Certoparin.Approved, Investigational
Chenodeoxycholic acidThe therapeutic efficacy of Chenodeoxycholic acid can be decreased when used in combination with Synthetic Conjugated Estrogens, B.Approved
CiclesonideThe serum concentration of Ciclesonide can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved, Investigational
Citric AcidSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClarithromycinThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Clemastine.Approved
ClobetasolThe serum concentration of Clobetasol can be increased when it is combined with Synthetic Conjugated Estrogens, B.Investigational
Clobetasol propionateThe serum concentration of Clobetasol propionate can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
ClobetasoneThe serum concentration of Clobetasone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
ClocortoloneThe serum concentration of Clocortolone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
ClotrimazoleThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Cobicistat.Approved
Conestat alfaSynthetic Conjugated Estrogens, B may increase the thrombogenic activities of Conestat alfa.Approved
ConivaptanThe serum concentration of Synthetic Conjugated Estrogens, B can be increased when it is combined with Conivaptan.Approved, Investigational
Cortexolone 17α-propionateThe serum concentration of Cortexolone 17α-propionate can be increased when it is combined with Synthetic Conjugated Estrogens, B.Investigational
CorticosteroneThe serum concentration of Corticosterone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Experimental
Cortisone acetateThe serum concentration of Cortisone acetate can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
CrizotinibThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Crizotinib.Approved
CyclosporineThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Synthetic Conjugated Estrogens, B can be decreased when it is combined with Dabrafenib.Approved
DalteparinSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Dalteparin.Approved
DanaparoidSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Darexaban.Investigational
DarunavirThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Synthetic Conjugated Estrogens, B can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Synthetic Conjugated Estrogens, B can be decreased when it is combined with Deferasirox.Approved, Investigational
DeflazacortThe serum concentration of Deflazacort can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
DelavirdineThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Delavirdine.Approved
DesirudinSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Desirudin.Approved
DesonideThe serum concentration of Desonide can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved, Investigational
DesoximetasoneThe serum concentration of Desoximetasone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
Desoxycorticosterone acetateThe serum concentration of Desoxycorticosterone acetate can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
Desoxycorticosterone PivalateThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Synthetic Conjugated Estrogens, B.Experimental, Vet Approved
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe serum concentration of Dexamethasone isonicotinate can be increased when it is combined with Synthetic Conjugated Estrogens, B.Vet Approved
DextranSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Dextran 40.Approved
Dextran 70Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Dextran 70.Approved
Dextran 75Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Dextran 75.Approved
DicoumarolSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Dicoumarol.Approved
DiflorasoneThe serum concentration of Diflorasone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
DifluocortoloneThe serum concentration of Difluocortolone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved, Investigational
DifluprednateThe serum concentration of Difluprednate can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
DihydroergotamineThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Diltiazem.Approved
DoxycyclineThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Dronedarone.Approved
DyphyllineThe serum concentration of Dyphylline can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
Edetic AcidSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Edoxaban.Approved
EnoxaparinSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Enoxaparin.Approved
EnzalutamideThe serum concentration of Synthetic Conjugated Estrogens, B can be decreased when it is combined with Enzalutamide.Approved
EquileninThe serum concentration of Equilenin can be increased when it is combined with Synthetic Conjugated Estrogens, B.Experimental
EquilinThe serum concentration of Equilin can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
ErythromycinThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Erythromycin.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
Ethyl biscoumacetateSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacEtodolac may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B.Approved, Investigational, Vet Approved
EtoricoxibEtoricoxib may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B.Approved, Investigational
ExemestaneThe therapeutic efficacy of Exemestane can be decreased when used in combination with Synthetic Conjugated Estrogens, B.Approved, Investigational
Ferulic acidSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Ferulic acid.Experimental
fluasteroneThe serum concentration of fluasterone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Investigational
FluconazoleThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Fluconazole.Approved
FludrocortisoneThe serum concentration of Fludrocortisone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
FluindioneSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Fluindione.Investigational
FlumethasoneThe serum concentration of Flumethasone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved, Vet Approved
FlunisolideThe serum concentration of Flunisolide can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved, Investigational
Fluocinolone AcetonideThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved, Investigational, Vet Approved
FluocinonideThe serum concentration of Fluocinonide can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved, Investigational
FluocortoloneThe serum concentration of Fluocortolone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved, Withdrawn
FluorometholoneThe serum concentration of Fluorometholone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
FluprednideneThe serum concentration of Fluprednidene can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved, Withdrawn
FluprednisoloneThe serum concentration of Fluprednisolone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
FlurandrenolideThe serum concentration of Flurandrenolide can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
Fluticasone propionateThe serum concentration of Fluticasone propionate can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
FluvoxamineThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Fluvoxamine.Approved, Investigational
FondaparinuxSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
FormestaneThe serum concentration of Formestane can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved, Investigational, Withdrawn
FosamprenavirThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Synthetic Conjugated Estrogens, B can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Synthetic Conjugated Estrogens, B can be increased when combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Synthetic Conjugated Estrogens, B can be increased when it is combined with Fusidic Acid.Approved
GabexateSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Gabexate.Investigational
HalcinonideThe serum concentration of Halcinonide can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved, Investigational, Withdrawn
HE3286The serum concentration of HE3286 can be increased when it is combined with Synthetic Conjugated Estrogens, B.Investigational
HeparinSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Heparin.Approved, Investigational
Human C1-esterase inhibitorSynthetic Conjugated Estrogens, B may increase the thrombogenic activities of Human C1-esterase inhibitor.Approved
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Synthetic Conjugated Estrogens, B.Approved, Investigational
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved, Vet Approved
IdraparinuxSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Idraparinux.Investigational
ImatinibThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Imatinib.Approved
IndinavirThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Indinavir.Approved
IsavuconazoniumThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Isavuconazonium.Approved, Investigational
IsradipineThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Isradipine.Approved
IstaroximeThe serum concentration of Istaroxime can be increased when it is combined with Synthetic Conjugated Estrogens, B.Investigational
ItraconazoleThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Synthetic Conjugated Estrogens, B can be increased when it is combined with Ivacaftor.Approved
KetoconazoleThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Ketoconazole.Approved, Investigational
LenalidomideSynthetic Conjugated Estrogens, B may increase the thrombogenic activities of Lenalidomide.Approved
LepirudinSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Lepirudin.Approved
LetaxabanSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Letaxaban.Investigational
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Synthetic Conjugated Estrogens, B.Approved
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Synthetic Conjugated Estrogens, B.Approved, Vet Approved
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Synthetic Conjugated Estrogens, B.Approved
LopinavirThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Lopinavir.Approved
LoteprednolThe serum concentration of Loteprednol can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
LovastatinThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Synthetic Conjugated Estrogens, B can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Synthetic Conjugated Estrogens, B can be increased when combined with Lumacaftor.Approved
LumiracoxibLumiracoxib may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B.Approved, Investigational
ME-609The serum concentration of ME-609 can be increased when it is combined with Synthetic Conjugated Estrogens, B.Investigational
MedrysoneThe serum concentration of Medrysone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
MelagatranSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Melagatran.Experimental
MelengestrolThe serum concentration of Melengestrol can be increased when it is combined with Synthetic Conjugated Estrogens, B.Vet Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved, Vet Approved
MifepristoneThe serum concentration of Synthetic Conjugated Estrogens, B can be increased when it is combined with Mifepristone.Approved, Investigational
MitotaneThe serum concentration of Synthetic Conjugated Estrogens, B can be decreased when it is combined with Mitotane.Approved
MometasoneThe serum concentration of Mometasone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved, Vet Approved
NabumetoneNabumetone may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B.Approved
NadroparinSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Nadroparin.Approved
NafamostatSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Nafamostat.Approved, Investigational
NCX 1022The serum concentration of NCX 1022 can be increased when it is combined with Synthetic Conjugated Estrogens, B.Investigational
NefazodoneThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Synthetic Conjugated Estrogens, B can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Synthetic Conjugated Estrogens, B can be increased when combined with Nevirapine.Approved
NilotinibThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Nilotinib.Approved, Investigational
OlaparibThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Olaparib.Approved
Oleoyl-estroneThe serum concentration of Oleoyl-estrone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Investigational
OsimertinibThe serum concentration of Synthetic Conjugated Estrogens, B can be increased when it is combined with Osimertinib.Approved
OspemifeneThe risk or severity of adverse effects can be increased when Synthetic Conjugated Estrogens, B is combined with Ospemifene.Approved
OtamixabanSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Otamixaban.Investigational
PalbociclibThe serum concentration of Synthetic Conjugated Estrogens, B can be increased when it is combined with Palbociclib.Approved
ParamethasoneThe serum concentration of Paramethasone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
ParecoxibParecoxib may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B.Approved
Pentaerythritol TetranitrateSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
PentobarbitalThe metabolism of Synthetic Conjugated Estrogens, B can be increased when combined with Pentobarbital.Approved, Vet Approved
Pentosan PolysulfateSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Pentosan Polysulfate.Approved
PhenindioneSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalThe metabolism of Synthetic Conjugated Estrogens, B can be increased when combined with Phenobarbital.Approved
PhenprocoumonSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenytoinThe metabolism of Synthetic Conjugated Estrogens, B can be increased when combined with Phenytoin.Approved, Vet Approved
PosaconazoleThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Synthetic Conjugated Estrogens, B.Approved, Nutraceutical
Prasterone sulfateThe serum concentration of Prasterone sulfate can be increased when it is combined with Synthetic Conjugated Estrogens, B.Investigational
PrednicarbateThe serum concentration of Prednicarbate can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved, Vet Approved
PregnenoloneThe serum concentration of Pregnenolone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Experimental, Investigational
PrimidoneThe metabolism of Synthetic Conjugated Estrogens, B can be increased when combined with Primidone.Approved, Vet Approved
Protein CSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Protein C.Approved
Protein S humanSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Protocatechualdehyde.Approved
RanolazineThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Ranolazine.Approved, Investigational
ReviparinSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Reviparin.Approved, Investigational
RifabutinThe metabolism of Synthetic Conjugated Estrogens, B can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Synthetic Conjugated Estrogens, B can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Synthetic Conjugated Estrogens, B can be increased when combined with Rifapentine.Approved
RimexoloneThe serum concentration of Rimexolone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
RivaroxabanSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Rivaroxaban.Approved
RofecoxibRofecoxib may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B.Investigational, Withdrawn
RopiniroleThe serum concentration of Ropinirole can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved, Investigational
SaquinavirThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Saquinavir.Approved, Investigational
SildenafilThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Synthetic Conjugated Estrogens, B can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Synthetic Conjugated Estrogens, B can be increased when it is combined with Simeprevir.Approved
SomatotropinThe therapeutic efficacy of Somatotropin can be decreased when used in combination with Synthetic Conjugated Estrogens, B.Approved, Investigational
St. John's WortThe serum concentration of Synthetic Conjugated Estrogens, B can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Synthetic Conjugated Estrogens, B can be increased when it is combined with Stiripentol.Approved
SulfisoxazoleThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulodexideSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Sulodexide.Approved, Investigational
TelaprevirThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Telithromycin.Approved
ThalidomideSynthetic Conjugated Estrogens, B may increase the thrombogenic activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe serum concentration of Theophylline can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Synthetic Conjugated Estrogens, B.Approved
TiclopidineThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Ticlopidine.Approved
TipranavirSynthetic Conjugated Estrogens, B may increase the dermatologic adverse activities of Tipranavir.Approved, Investigational
TixocortolThe serum concentration of Tixocortol can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TocilizumabThe serum concentration of Synthetic Conjugated Estrogens, B can be decreased when it is combined with Tocilizumab.Approved
TriamcinoloneThe serum concentration of Triamcinolone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved, Vet Approved
TroxerutinSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe serum concentration of Ulobetasol can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
Ursodeoxycholic acidThe therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Synthetic Conjugated Estrogens, B.Approved, Investigational
ValdecoxibValdecoxib may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B.Investigational, Withdrawn
VenlafaxineThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Verapamil.Approved
Vitamin CThe serum concentration of Synthetic Conjugated Estrogens, B can be increased when it is combined with Vitamin C.Approved, Nutraceutical
VoriconazoleThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Warfarin.Approved
XimelagatranSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZiprasidoneThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Ziprasidone.Approved
Food Interactions
Not Available

References

General References
  1. Bhamra R, Kaercher U, Oleary CM: Pharmacokinetics of a modified-release estrogen tablet. J Reprod Med. 2010 Sep-Oct;55(9-10):404-10. [PubMed:21043366]
  2. 14. (2015). In Pharmacology for Women’s Health. Jones & Bartlett Publishers.
External Links
KEGG Drug
D05987
PubChem Substance
347910438
ChEMBL
CHEMBL1201467
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Conjugated_estrogen
FDA label
Download (7.08 MB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentMenopause1
4CompletedTreatmentNocturnal Vasomotor Symptoms1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
TabletOral.3 mg/1
TabletOral.625 mg/1
TabletOral.9 mg/1
Tablet, film coatedOral.3 mg/1
Tablet, film coatedOral.45 mg/1
Tablet, film coatedOral.9 mg/1
Tablet, film coatedOral1.25 mg/1
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6660726No2001-03-082021-03-08Us
US6855703No2001-02-122021-02-12Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Ligand
General Function
Zinc ion binding
Specific Function
Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissu...
Gene Name
ESR1
Uniprot ID
P03372
Uniprot Name
Estrogen receptor
Molecular Weight
66215.45 Da

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da

Drug created on November 17, 2015 10:11 / Updated on November 06, 2017 06:46